Fig. 1 18F-FDG PET/CT is a sensitive molecular imaging modality for monitoring therapeutic response to chemotherapy in lymphoma, lung cancer etc. Molecular response is noted in the primary tumor and mediastinal…

Nuclide Radiation type T1/2 Eβ.max p Eγ p Dose rate [mSv/h GBq] [keV] [%] [keV] [%] in 30 cm from point sourcea in contact with 5 ml syringe P-32 β- 14.3 d 1710…

Fig. 1 Approximate time course of clinical manifestations following exposure to levels from 1 to over 2 Gy. George et al. (2007) The early or prodromal phase response from exposure to ionizing…

Radionuclide Emission Half-life Range Approximate cell diameters 131Iodine ß 8.0 d 0.08–2.3 mm 10–230 90Yttrium ß 64.1 h 4.0–11.3 mm 400–1100 177Lutetium ß 6.7 d 0.04–1.8 mm 4–180 188Rhenium ß 17.0 h 1.9–10.4 mm 200–1000 67Copper ß 61.9 d…

Fig. 1 Targeted and activatable probes are the kinds of agent used most widely in molecular imaging. Targeted probes bind via a ligand to their designated target, with the prototypical ligand…

Fig. 1 Cavities on the β-subunit of HLA-DR10 that were used to develop a series of B cell lymphoma specific SHALs. The three cavities selected for use as ligand-binding sites are…

Fig. 1 ICRU target volumes The second important tool for the planning of percutaneous irradiations are DVHs. Here, the dose given to a certain structure like a target volume or a…

  P-32 Y-90 Re-86 Er-169 Radiation B B B and G B and G Particle size (u) 6–20 10–20 0.1 1000–2000 nm Penetration (mm) 3–5 4–10 1–4 0.1–0.4 Half-life (days) 14…

Fig. 1 Decay scheme of the 223Ra series 4.1 Some Historical Remarks The discovery of radium (L. Radius, ray) by Marie and Pierre Curie in 1898, represents a unique chapter in…

Therapeutic nuclide Diagnostic nuclide (positron emitter) Nuclide Half-life Nuclide Half-life β+ branching (%) Availability Isotopic substituent 131I 8.04 d 124I 4.18 d 23 Cyclotron   122I 3.62 min 77 Cyclotron, generator 122Xe/122I…